BioSpace News Archive

Hemab Therapeutics announced results from preclinical research of HMB-001 in models of factor VII deficiency at the International Society on Thrombosis and Haemostasis 2023 Congress in Montreal.

A new trial revealed data on the effects of bempedoic acid – a non-statin cholesterol-lowering drug – on cardiovascular outcomes, demonstrating that patients with risk factors for coronary artery disease and high cholesterol, particularly those with diabetes, should be treated with a cholesterol-lowering drug.

Rallybio Corporation reported data from the Phase 1b proof-of-concept study of RLYB212, a novel monoclonal anti-HPA-1a antibody in development for the prevention of fetal and neonatal alloimmune thrombocytopenia.

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering new approaches to the treatment of type 2 diabetes, presented preclinical findings from its Rejuva® program at the American Diabetes Association’s 83rd Scientific Sessions.

Novo Nordisk announced that data from the phase 3a ONWARDS 1 and 3 trials evaluating investigative once-weekly insulin icodec, which were presented at the 83rd Annual Scientific Sessions of the American Diabetes Association, showed the studies met their primary endpoints and insulin icodec provided similar glucose-lowering effects while reducing injections from seven to one per week compared with once-daily basal insulin1-2.

Results from two studies evaluating the impact of mental health support for diabetes patients found significant benefits in patient outcomes were presented at the 83rd Scientific Sessions of the American Diabetes Association® in San Diego, CA.